title: Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol.
authors: Janssen Research & Development, LLC, Raritan, New Jersey, USA.
authors: Dainius A
authors: DA
authors: Balis
authors: Cindy
authors: C
authors: Tong
authors: Gary
authors: G
authors: Meininger
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D000068896:Canagliflozin; D003847:Deoxyglucose / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D005500:Follow-Up Studies; D005960:Glucosides / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D011379:Prognosis; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D000068896:Canagliflozin; D003847:Deoxyglucose; D005960:Glucosides; D006442:Glycated Hemoglobin; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes; C006584:1,5-anhydroglucitol
keywords: 1,5-anhydroglucitol; GlycoMark®; canagliflozin; sodium-glucose cotransporter 2 inhibitor